HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 34, 31521-31527, August 24, 2001

This Article Abstract Full Text (PDF) All Versions of this Article: 276/34/31521    most recent M103306200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawrence, J. W. Articles by Zhou, G. Search for Related Content PubMed PubMed Citation Articles by Lawrence, J. W. Articles by Zhou, G. Social Bookmarking                      What's this?

Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR)

PPAR FAILS TO INDUCE PEROXISOME PROLIFERATION-ASSOCIATED GENES IN HUMAN CELLS INDEPENDENTLY OF THE LEVEL OF RECEPTOR EXPRESSION^*

Jeffrey W. Lawrence^§, Ying Li^¶, Shiying Chen^¶, John G. DeLuca, Joel P. Berger^¶, Diane R. Umbenhauer, David E. Moller^¶, and Gaochao Zhou^¶

From the  Department of Safety Assessment, Merck Research Laboratories, Merck and Co., Inc., West Point, Pennsylvania and ^¶ Department of Metabolic Disorders, Merck Research Laboratories, Merck and Co., Inc., Rahway, New Jersey

Received for publication, April 13, 2001, and in revised form, June 11, 2001

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We compared the ability of rat and human hepatocytes to respond to fenofibric acid and a novel potent phenylacetic acid peroxisome proliferator-activated receptor (PPAR)  agonist (compound 1). Fatty acyl-CoA oxidase (FACO) activity and mRNA were increased after treatment with either fenofibric acid or compound 1 in rat hepatocytes. In addition, apolipoprotein CIII mRNA was decreased by both fenofibric acid and compound 1 in rat hepatocytes. Both agonists decreased apolipoprotein CIII mRNA in human hepatocytes; however, very little change in FACO activity or mRNA was observed. Furthermore, other peroxisome proliferation (PP)-associated genes including peroxisomal 3-oxoacyl-CoA thiolase (THIO), peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), peroxisomal membrane protein-70 (PMP-70) were not regulated by PPAR agonists in human hepatocytes. Moreover, other genes that are regulated by PPAR ligands in human hepatocytes such as mitochondrial HMG-CoA synthase and carnitine palmitoyl transferase-1 (CPT-1) were also regulated in HepG2 cells by PPAR agonists. Several stably transfected HepG2 cell lines were established that overexpressed human PPAR to levels between 6- and 26-fold over normal human hepatocytes. These PPAR-overexpressing cells had higher basal mRNA levels of mitochondrial HMG-CoA synthase and CPT-1; however, basal FACO mRNA levels and other PP-associated genes including THIO, HD, or PMP-70 mRNA were not substantially affected. In addition, FACO, THIO, HD, and PMP-70 mRNA levels did not increase in response to PPAR agonist treatment in the PPAR-overexpressing cells, although mitochondrial HMG-CoA synthase and CPT-1 mRNAs were both induced. These results suggest that other factors besides PPAR levels determine the species-specific response of human and rat hepatocytes to the induction of PP.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Chemicals that elicit the phenomenon of peroxisome proliferation in rodents are associated with hepatocarcinogenesis in long-term studies (reviewed in Ref. 1). The tumorigenic response seems related to both the oxidative stress and increased cell proliferation observed after treatment with these chemicals. It has been demonstrated that non-rodent species are refractory to the induction of peroxisome proliferation (2-4); however, humans are not totally unresponsive to treatment with PPAR¹ agonists. For example, the expression of apo CIII, a lipoprotein involved in triglyceride transport, is suppressed by PPAR agonsits in rodents and humans and is involved in the hypotriglyceridemic effects of PPAR agonists observed clinically (5). In addition, mitochondrial HMG-CoA synthase, a gene involved in regulating ketogenesis, is responsive to PPAR agonist treatment independently of the ability of the species to respond by inducing peroxisome proliferation (6). Thus, species differences in response to peroxisome proliferation induction appear distinct from PPAR activation. There are several potential explanations for the species-specific differences in response to the induction of peroxisome proliferation. One hypothesis suggests that the difference between rodents and non-rodents in their susceptibility to peroxisome proliferation is related to the difference in relative expression of PPAR between the species (7-10). For example, human liver seems to express PPAR at levels that are approximately an order of magnitude lower than rat liver (11). It is possible, if the amount of the PPAR is limiting, that only a subset of genes may be induced upon exposure to ligand. Another hypothesis is that the response element is defective in non-rodent species (12, 13) and that the receptor cannot bind to or regulate the genes because they do not have functional PPREs within their promoters. Indeed, when several human genomic samples were analyzed, sequence analysis found that their fatty acyl-CoA oxidase promoter contained disrupted PPRE sequences.

In these studies, we compared the response of rat and human hepatocytes to the effects of fenofibric acid and a novel potent phenylacetic acid PPAR agonist (compound 1). In addition, we developed several HepG2 cell lines with different levels of human PPAR overexpression and determined the effect of overexpression on basal and ligand-stimulated expression of several genes known to be responsive in both rat and human hepatocytes as well as peroxisome proliferation-associated genes that are only responsive in rat hepatocytes.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Primary Hepatocytes-- Rat hepatocytes were isolated by a standard two-stage collagenase perfusion (14), plated in Williams E medium containing 10% fetal bovine serum, 1 µM dexamethasone, 1 µM insulin, 20 µg/ml gentamicin, 292 mg/ml L-glutamine, and 50 mM HEPES on rat-tail collagen, and allowed to attach and recover from isolation overnight at 37 °C. Approximately 24 h after isolation, fresh medium with all additions except fetal bovine serum and containing the appropriate concentration of fenofibric acid or compound 1 ((3-chloro-4-((3-((3-phenyl-7-propyl-1-benzofuran-6-yl)oxy)propyl)thio)phenyl)acetic acid, Merck Research Laboratories, Rahway, NJ) was added to the cells as a 100× stock in Me₂SO. The culture medium was replaced at 24 h and after 48 h of treatment, the cells were rinsed with 100 mM NaPO₄, pH 7.4, and harvested by scraping. The cells were disrupted by sonication and the resulting homogenates were assayed for protein concentration by the Lowry procedure (15) and frozen at 70 °C. Human hepatocytes were obtained commercially from Clonetics Corp. (San Diego, CA) as cultures already attached to collagen in proprietary medium. They arrived ~24 h post-isolation and were allowed to recover from shipping overnight at 37 °C prior to use. Subsequently, the human hepatocytes were treated and processed as indicated above with the exception that the Clonetics proprietary medium was used at medium changes and during treatment.

Homogeneous Time-resolved Fluorescence-based Nuclear Receptor Association Assay-- A homogeneous time-resolved fluorescence assay-based nuclear receptor-coactivator assay was used to examine the interaction of hPPAR with compound 1. A complete description of this assay has been published elsewhere (16). Briefly, 198 µl of reaction mixture (100 mM HEPES, 125 mM KF, 0.125% (w/v) CHAPS, 0.05% dry milk, 5 nM GST-hPPARLBD, 2 nM anti-GST-(Eu)K, 10 nM biotin-CBP-(1-453), and 20 nM SA/XL665) were added to each well followed by the addition of 2 µl of Me₂SO or compound 1 (in Me₂SO) in appropriate wells. The plates were mixed by hand and covered with TopSeal. The plates were incubated overnight at 4 °C followed by fluorescence measurement on a Discovery instrument (Packard). The data were reported as a ratio of the fluorescence at 665 nm (XL665, A counts) to the fluorescence at 620 nm (Eu(K), B counts) multiplied by 10,000 (to give a whole number). The plasmid expressing GST-hPPARLBD was constructed by PCR the cloning of the hPPAR sequence encoding the ligand binding domain (from amino acid 167 to 468) into a GST vector. The GST-hPPARLBD fusion protein was purified as described (16).

PPAR-GAL4 Chimeric Receptor Transactivation Assay-- Transactivation by human or murine PPAR was determined in transiently cotransfected in COS-1 cells as described (17) using pSG5-hPPAR-GAL4 or pSG5-mPPAR-GAL4, and both pUAS(5X)-tk-luciferase and pCMV-lacz were then incubated with the indicated concentrations of compound 1 for 48 h.

HepG2 Cells and Stably Transfected HepG2 Cells Overexpressing hPPAR-- HepG2 cells were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. The hPPAR expression construct, pIRES1neo-hPPAR, was constructed by PCR subcloning of the sequence encoding full-length hPPAR into pIRES1neo (CLONTECH). The hPPAR coding sequence was resequenced to confirm the absence of PCR error. HepG2 cells were transfected with pIRES1neo-hPPAR using a standard LipofectAMINE method (Life Technologies, Inc.). Stably transfected cell lines were selected in the presence of 0.5 mg/ml G418 for 3 weeks with the culture medium changed twice a week. Individual G418-resistant colonies were clone-purified followed by immunoblot and RNA analysis by the 5'-nuclease RT-PCR assay to verify hPPAR expression. The cell lysates were obtained by the direct addition of SDS sample buffer without dithiothreitol. The protein concentration was determined using the BCA method (Pierce). Western blots were performed as described using an anti-PPAR antibody (18).

Fatty Acyl-CoA Oxidase Activity-- Fatty acyl-CoA oxidase activity was assayed by monitoring the evolution of H₂O₂ as described by Poosch and Yamazaki (19) using lauryl-CoA as the substrate and 1 mM hydroxyphenylacetic acid as the indicator. Incubations were carried out at 37 °C for 10 min for the rat homogenates and 15 min for the human homogenates and stopped with 2 mM KCN in carbonate buffer. All samples were assayed in duplicate with a corresponding blank (lacking lauryl-CoA) subtracted. The results were converted to nanomoles of product by comparison to an H₂O₂ standard curve and normalized to milligrams of protein.

Northern Analysis-- Total RNA was isolated from cells with 1 ml of Triazol reagent (Life Technologies, Inc.) following manufacturer instructions. RNA was quantified by spectrophotometry at 260 nm. Rat and human apo CIII DNA probes were generated by RT-PCR from isolated rat or human total RNA using primers derived from published sequences (20, 21). Purified PCR-generated DNA fragments of rat and human apo CIII and an 18S rRNA DNA template were labeled with a psoralen-biotin kit. Northern analysis was performed using a Tris borate EDTA-urea polyacrylamide gel electrophoresis gel system. RNA was then electroblotted to a positively charged nylon membrane and cross-linked with UV irradiation. Blots were hybridized with a biotinylated apo CIII probe overnight and washed, and the biotinylated probe was detected with a streptavidin-alkaline phosphatase conjugate and a chemiluminescent substrate. The chemiluminescent signal was detected by exposure to x-ray film and quantified by densitometry. Probes were stripped, and the filter was reprobed with biotinylated 18S rRNA probe, detected by chemiluminescence, and quantified as above. The data are expressed as the ratio of apo CIII to 18S rRNA.

5'-Nuclease RT-PCR Assay-- Fatty acyl-CoA oxidase (FACO), carnitine pamitoyltransferase-1 (CPT-1), peroxisomal 3-oxoacyl-CoA thiolase (THIO), peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase (HD), cytochrome P450 4A (CYP4A), peroxisomal membrane protein-70 (PMP-70), and mitochondrial HMG-CoA synthase (HMG-CoA synthase) mRNAs were quantified using real-time RT-PCR. cDNA synthesis was performed in 25 µl with 0.1 µg total RNA with the TAQMAN^® RT kit (PerkinElmer Life Sciences) with the following conditions: 25 °C for 10 min, 48 °C for 30 min, and 95 °C for 5 min. After reverse transcription, a 3-µl aliquot was transferred into a 25-µl TAQMAN^® amplification reaction (TAQMAN^® PE 2× PCR Mastermix diluted to a 1× final concentration) containing primer/probes for 18S rRNA (JOE-tagged: 6-carboxy-4',5'-dichloro-2',7'-dimethylfluorescein) and either rat or human FACO, CPT-1, THIO, HD, CYP4A, PMP-70, or HMG-CoA synthase (6-FAM tagged: 6-carboxyfluorescein) with the following conditions: 50 °C for 2 min, 95 °C for 10 min and amplified at 95 °C for 15 s, and 60 °C for 1 min for 40 cycles.

The specific sequences of the primers and probes are listed in Table I.

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

PPAR Is Active in Both Rat and Human Hepatocytes But Regulates FACO Activity Only in Rat Hepatocytes-- After treatment with fenofibric acid for 48 h, a dose-dependent increase in FACO activity was observed in rat hepatocytes (Fig. 1). At 100 µM, fenofibric acid produced a 6-fold increase in FACO activity. No increase in FACO activity was observed in human hepatocytes. In parallel culture dishes, fenofibric acid produced a dose-dependent suppression of apo CIII mRNA levels in both rat and human at the doses that corresponded to those that induced FACO activity in rat hepatocytes. A novel highly potent phenylacetic acid PPAR agonist (compound 1) was used to assess the effects of a more potent PPAR agonist in this system. This compound has high potency on the human PPAR receptor but is a weak agonist on the murine receptor. Based on the ability of PPAR to recruit the CBP coactivator in vitro, the estimated EC₅₀ for compound 1 on human PPAR is 16 nM and is ~10 µM on the murine receptor (Fig. 2A). Concentrations greater than 10 µM could not be tested in the homogeneous time-resolved fluorescence-based nuclear receptor association assay because of the quenching effect of the compound. These values corresponded well with results using chimeric human or murine PPAR-GAL4 receptor transactivation reporter assays (Fig. 2B). When compound 1 was assessed in rat hepatocytes, FACO activity was induced slightly at doses above 1 µM, corresponding to the weak potency on rodent PPAR (Fig. 3). Doses higher than 10 µM of compound 1 were cytotoxic to the rat and human hepatocytes. Compound 1 also suppressed apo CIII mRNA at doses above 1 µM. Only a very modest effect of compound 1 was observed in human hepatocytes on FACO activity (~2-fold) at doses up to 10 µM; however, apo CIII mRNA was suppressed at doses as low as 10 nM. The effects on apo CIII corresponded with its potency on the human PPAR.

View larger version (20K): [in this window] [in a new window]   Fig. 1.   Fenofibric acid induces FACO activity and suppresses apo CIII mRNA in rat hepatocytes but only suppresses apo CIII mRNA in human hepatocytes. Rat or human primary hepatocytes were cultured for 48 h in the presence or absence of various concentrations of fenofibric acid and then harvested for FACO activity determinations or apo CIII mRNA Northern analysis as described under "Experimental Procedures." The apo CIII signal was corrected by reprobing with an 18S rRNA probe and dividing the apo CIII signal by the 18S rRNA signal. The data are expressed as nmol of H2O2/min/mg of protein for FACO activity or relative to untreated controls for apo CIII (mean ± S.E., n = 4). , rat hepatocytes; , human hepatocytes.

View larger version (19K): [in this window] [in a new window]   Fig. 2.   Compound 1 is a potent human but weak murine PPAR agonist. A, the ability of compound 1 (the inset shows the structure) to promote human () or murine () PPAR and CBP interaction was analyzed using an homogeneous time-resolved fluorescence-based nuclear receptor assay in the presence of 10 nM SA/XL665, 10 nM biotin-CBP-(1-453), 1 nM GST-PPARLBD, and 2 nM anti-GST-(Eu)K as described under "Experimental Procedures." The 665 nm/620 nm ratio for each well was normalized by subtracting that obtained from the control well followed by calculation of the percentage maximum activation (using maximal ligand-induced fluorescence resonance energy transfer as 100%). The titration using human GST-PPARLBD is shown. Each point represents the mean ± S.E. of three determinations. The experiment was repeated with similar results. B, transactivation by human () or murine () PPAR in COS-1 cells transiently cotransfected with pSG5-hPPAR-GAL4 or pSG5-mPPAR-GAL4 chimeric constructs and both pUAS(5X)-tk-luciferase and pCMV-lacz then incubated with the indicated concentrations of compound 1 for 48 h. The data are expressed as the mean ± S.E. of normalized luciferase activity (n = 3).

View larger version (18K): [in this window] [in a new window]   Fig. 3.   Compound 1 induces FACO activity and suppresses apo CIII mRNA in rat hepatocytes but only suppresses apo CIII mRNA in human hepatocytes. Rat or human primary hepatocytes were cultured for 48 h in the presence or absence of various concentrations of compound 1 and then harvested for FACO activity determinations or apo CIII mRNA Northern analysis as described under "Experimental Procedures." The apo CIII signal was corrected by reprobing with an 18S rRNA probe and dividing the apo CIII signal by the 18S rRNA signal. The data are expressed as nmol of H2O2/min/mg of protein for FACO activity or relative to untreated controls for apo CIII (mean ± S.E., n = 4). , rat hepatocytes; , human hepatocytes.

PPAR Agonists Do Not Regulate Peroxisome Proliferation-associated Genes in Human Hepatocytes or HepG2 Cells-- The effects of fenofibric acid and compound 1 were assessed on genes potentially regulated by PPAR in rat and human hepatocytes. Messenger RNA for the peroxisome proliferation-associated genes including FACO, THIO, HD, CYP4A1, and PMP-70 were induced by fenofibric acid and compound 1 in rat hepatocytes (Fig. 4A). In rat hepatocytes, fenofibric acid was more efficacious than compound 1 probably because of the ability to test higher doses of fenofibric acid in rat hepatocytes without inducing frank cytotoxicity. Because of the decreased potency and limited concentration of compound 1 that could be tested, a more modest increase was observed. In human hepatocytes, no increase in the peroxisome proliferation-associated genes was observed (Fig. 4B). A small increase in CYP4A11 mRNA was observed in human hepatocytes with compound 1; however, the magnitude was more than 25-fold less than that observed in rat hepatocytes. Two genes were responsive to fenofibric acid and compound 1 in human hepatocytes, CPT-1 and mtHMGS. When the same set of genes was examined in HepG2 cells, no response to either fenofibric acid or compound 1 was observed for the mRNA for the peroxisome proliferation-associated genes FACO, THIO, HD, FACO, or PMP-70 (Fig. 4C). Similar to what was observed in human hepatocytes, CPT-1 and mtHMGS both were induced after treatment. Interestingly, mtHMGS and CPT-1 basal mRNA levels were much lower in the HepG2 cells than in human hepatocytes. Basal mRNA levels of FACO, THIO, and HD were similar to those in human hepatocytes, whereas basal mRNA levels of PMP-70 were 4-5-fold higher than those in human hepatocytes. There was no detectable CYP4A11 mRNA in HepG2 cells.

View larger version (16K): [in this window] [in a new window]   Fig. 4.   Fenofibric acid and compound 1 induce mitochondrial HMG-CoA synthase and CPT-1 in human and rat heptocytes and HepG2 cells, but peroxisome proliferator-associated genes are induced only in rat hepatocytes. Rat hepatocytes (A), human hepatocytes (B), or HepG2 cells (C) were cultured for 48 h in the absence (open bars) or presence of 100 µM Fenofibric acid (solid bars) or 100 nM compound 1 (hatched bars) and harvested, and total RNA was isolated as described under "Experimental Procedures." The specific mRNAs were quantified by the 5'-nuclease RT-PCR assay and expressed relative to untreated cells (rat and human hepatocytes) or relative to untreated human hepatocytes (mean ± S.D., n = 2-4).

Overexpression of hPPAR Does Not Sensitize Human Cells to Induction of Peroxisome Proliferation-associated Genes-- Several stable HepG2 cell lines were created that overexpress human PPAR. The cell lines expressed from 6- to 26-fold higher levels of human PPAR mRNA than in primary human hepatocytes (Fig. 5). When three of these cell lines were assessed by Western analysis, they demonstrated markedly increased expression of PPAR protein. Some cell lines had higher protein levels than would be expected from their mRNA analysis (compare cell line J35 to J14). Basal levels of the selected mRNAs mentioned above were measured via the 5'-nuclease RT-PCR assay. Increasing levels of PPAR overexpression in these cells increased the basal levels of mtHMGS and CPT-1 mRNA (Fig. 6). The effect on basal levels of mtHMGS mRNA appeared to be saturable; however, the basal regulation of CPT-1 mRNA was not. In contrast, the peroxisome proliferation-associated genes FACO, THIO, HD, and PMP-70 were not mRNA affected substantially by increasing the amount of PPAR in the cell. PMP-70 did increase modestly, but that may be because of the much higher basal levels in HepG2 cells compared with human hepatocytes. The regulation of the same set of genes was assessed in the J35 cell line (10-fold higher PPAR levels than human hepatocytes) after treatment with 100 nM compound 1 (Fig. 7). Similar to the results found in primary human hepatocytes, both mtHMGS and CPT-1 mRNA were strongly induced after treatment; however, mRNA for the peroxisome proliferation-associated genes FACO, THIO, HD, and PMP-70 were not affected substantially by compound 1 treatment (Fig. 7). PMP-70 mRNA levels were increased modestly by compound 1; however, the magnitude of this change was small (less than 2-fold) compared with the induction observed in rat hepatocytes (6-7-fold). Thus, no meaningful induction of peroxisome proliferator-associated genes was observed regardless of the amount of PPAR in the cell.

View larger version (13K): [in this window] [in a new window]   Fig. 5.   Stable hPPAR-expressing cell lines express increased amounts of hPPAR. Total protein extracts (40 µg) from HepG2 cells or stable HepG2 cells that overexpress hPPAR were analyzed by SDS-polyacrylamide gel electrophoresis (4-20%) and Western blotting with an antibody against PPAR as described under "Experimental Procedures." The arrow indicates hPPAR protein. The B56 cell line was not available for Western analysis. Human PPAR mRNA levels were determined from total RNA from each HepG2 cell line by the 5'-nuclease RT-PCR assay, and the amount of hPPAR mRNA was expressed relative to untreated human hepatocytes.

View larger version (22K): [in this window] [in a new window]   Fig. 6.   Basal mRNA levels of mitochondrial HMG-CoA synthase and CPT-1 are regulated in HepG2 cells expressing increased hPPAR levels, but peroxisome proliferator-associated genes are not. Stable hPPAR-overexpressing cells were harvested, and total RNA was isolated as described under "Experimental Procedures." The specific mRNAs were quantified by the 5'-nuclease RT-PCR assay and expressed relative to untreated human hepatocytes. Open bars, parent HepG2; solid bars, J38 line with 6-fold higher PPAR levels than human hepatocytes; right-hatched bars, J35 line with 10-fold higher PPAR levels than human hepatocytes; left-hatched bars, J14 line with 16-fold higher PPAR levels than human hepatocytes; cross-hatched bars, B56 line with 26-fold higher PPAR levels than human hepatocytes.

View larger version (17K): [in this window] [in a new window]   Fig. 7.   Compound 1 induces mRNA for mitochondrial HMG-CoA synthase and CPT-1 in HepG2 cells expressing hPPAR at levels similar to rat hepatocytes but still does not induce peroxisome proliferator-associated genes. Stable hPPAR-overexpressing cells (J35 clone) were cultured for 48 h in the absence (open bars) or presence (solid bars) of 100 nM compound 1 and harvested, and total RNA was isolated as described under "Experimental Procedures." The specific mRNAs were quantified by the 5'-nuclease RT-PCR assay and expressed relative to untreated human hepatocytes (mean ± S.D.; n = 2-4).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

We compared rat and human cells to investigate mutual versus species-specific responses to PPAR agonists. Rat hepatocytes responded to PPAR agonist treatment by inducing the mRNA for several peroxisome proliferation-related genes including FACO, HD, THIO, CYP4A, and PMP-70 and had increased fatty acyl-CoA oxidase activity. In addition, PPAR agonist treatment suppressed apo CIII mRNA at the same doses that induced FACO activity. Fibrates regulate apo CIII through a PPRE in the promoter of the apo CIII gene (5), and the regulation of apo CIII is absent in PPAR knockout mice (data not shown). Thus, suppression of apo CIII mRNA can be considered a measure of PPAR activation in vivo. Consistent with their in vitro pharmacologic profile on murine PPAR, the potency of fenofibric acid and compound 1 were similar at suppressing apo CIII mRNA levels in rat hepatocytes. In addition, compound 1 produced similar effects as other PPAR agonists in rat hepatocytes on FACO activity.

Both compound 1 and fenofibric acid suppressed apo CIII mRNA levels in human hepatocytes; however, compound 1 was found to have at least a 1000-fold greater potency than fenofibric acid in these cells. This difference in potency correlated with the ability of compound 1 to function as a very potent human PPAR agonist as assessed by its ability to transactivate a reporter construct or recruit CBP in the in vitro interaction assay, which is a more direct measure of PPAR affinity. Mukherjee et al. (22) have observed that WY14,643 was more potent at activating the rat PPAR than the human PPAR. In addition, they observed that ETYA was more potent on the human PPAR than on the rat PPAR. Our results are consistent with these findings and suggest that human and rodent PPARs can be distinguished pharmacologically. There are two amino acids that differ in the ligand-binding domain of PPAR between rat and human. These differences in amino acid sequence may explain the differences in the potency of the various ligands for each of the species receptors.

In contrast to rat hepatocytes, the doses of fenofibric acid or compound 1 that effectively suppressed apo CIII mRNA levels were not associated with FACO activity increases in human cells, even though apo CIII mRNA levels were suppressed at doses as low as 10 nM compound 1. Thus, when a highly potent human PPAR ligand is incubated with human cells, even at doses 1000 times higher than required to fully activate the human PPAR (as measured by apo CIII mRNA suppression), no substantial induction of the peroxisome proliferation-associated genes was observed. These data dispel the concern that the previously assessed ligands in human cells were not potent enough to fully activate the human PPAR receptor. In addition, our data demonstrate that the maximal PPAR activation potential of both fenofibric acid and compound 1 were similar in rat and human hepatocytes because apo CIII mRNA was ultimately suppressed by ~80% in both species. Our data are also consistent with previous studies that have found that species other than rats and mice are resistant to the induction of peroxisome proliferation in vitro (2, 5, 23, 24).

Our data also demonstrate that HepG2 cells responded to PPAR agonist treatment in a similar fashion to human hepatocytes by inducing CPT-1 and mtHMGS mRNAs. Previous reports have demonstrated that CPT-1 and mtHMGS are regulated by PPAR through PPREs in their respective promoters (6, 25, 26). None of the peroxisome proliferation-associated genes including FACO, HD, THIO, or PMP-70 were responsive to PPAR agonist treatment in HepG2 cells.

Several PPAR-overexpressing HepG2 cell lines were studied to assess the effects of PPAR expression levels on basal and ligand-stimulated regulation of CPT-1 and mtHMGS and the peroxisome proliferation-associated genes. We found that HepG2 cells expressed similar levels of FACO, THIO, and HD mRNA as human hepatocytes. However, HepG2 cells have lower peroxisomal -oxidation rates than human hepatocytes as well as lower protein levels of these genes (27). HepG2 cells cultured under our conditions had markedly higher PMP-70 mRNA levels than human hepatocytes. Thus, the regulation of the peroxisomal -oxidation proteins may occur, in part, independently of PPAR and through a post-transcriptional mechanism. Interestingly, we found that genes regulated in parental HepG2 cells by PPAR ligands (CPT-1 and mtHMGS) were also induced by the stable overexpression of PPAR. In contrast, genes that were not responsive to PPAR ligands in human hepatocytes or HepG2 cells were likewise unaffected by increasing PPAR content in the HepG2 cells. Furthermore, treatment with compound 1 induced both the regulated genes (CPT-1 and mtHMGS) even further in the PPAR-overexpressing HepG2 cells but had no effect on the peroxisome proliferation-associated genes. Thus, increasing PPAR expression levels to those found in rat hepatocytes failed to render human cells responsive to the induction of classical markers of peroxisome proliferation. It has been observed that HepG2 cells in long-term culture can display features of a more differentiated state (28). During this process PPAR mRNA expression levels increased up to 4-fold; however, basal levels of FACO, HD, THIO, and PMP-70 mRNA remained unchanged, consistent with these studies using the stably transfected HepG2 cells lines.

One question that remains is whether genes implicated in mediating cell proliferation are also affected by PPAR overexpression. Our study did not include such measurements because of the transformed phenotype of the HepG2 cells. Furthermore, unlike the well characterized gene pathways that modulate peroxisomal or mitochondrial fatty acid oxidation, PPAR-regulated genes that may contribute to observed increases in cell proliferation in rodent hepatocytes are not well defined.

There are numerous hypotheses that attempt to address the mechanism of species differences in the responsiveness to the induction of peroxisome proliferation between rodents and humans (7, 29-31). This issue is central for understanding potential human risk associated with the use of fibrates and the development of newer PPAR agonists for dyslipidemia, atherosclerosis, or other indications. Our understanding of the mechanism of action of peroxisome proliferators has been improved through the identification of PPAR as the central regulator of the pleiotropic responses of these agents in rodents (32, 33). It has been hypothesized that the difference in responsiveness of rodents and non-rodents to peroxisome proliferators depends on the amount of PPAR in each species. Humans express ~10 times less PPAR in the liver than rats (11, 22, 34). Our studies have demonstrated clearly that increasing the amount of human PPAR in a human liver cell line does not result in concomitant increased sensitivity to the induction of peroxisome proliferation. Genes that were previously regulated in human cells by PPAR ligands continued to be responsive to PPAR ligands after overexpression. Neither basal nor ligand-stimulated regulation of the peroxisome proliferation-associated genes was conferred by overexpressing PPAR. Macdonald et al. (35) have reported that the transfection of guinea pig hepatocytes with murine PPAR conferred responsivity to the induction of peroxisome proliferation. These studies found a 20-fold induction of peroxisomal -oxidation in primary rat hepatocytes and a less than 3-fold induction in primary guinea pig hepatocytes. Basal levels of peroxisomal -oxidation in guinea pig hepatocytes were modified modestly by PPAR transfection; however, ligand-stimulated peroxisomal -oxidation was increased by only 3-fold, the same as in untransfected guinea pig hepatocytes. The variability in these studies was quite high (50% or more in many cases) and may be the result of variable transfection efficiencies between samples. It could be possible that PPAR modulated the expression of another transcription factor that interacts with the acyl-CoA oxidase promoter and modified basal peroxisomal -oxidation activity. This would explain why the response to ligand remained unchanged. It is unknown whether the guinea pig acyl-CoA oxidase promoter contains a functional PPRE. The sequence of the guinea pig acyl-CoA oxidase promoter will be required to resolve the role of PPAR in guinea pig responsivity to peroxisome proliferation.

Another hypothesis suggests that humans are less sensitive to peroxisome proliferation induction because human cells express a dominant negative form of PPAR derived from a truncated transcript (36). Our data suggest a different mode of regulation than through depletion of co-factors as suggested by Gervois et al. (36), because providing as little as 6-fold additional PPAR (based on mRNA levels) was sufficient to confer the ability to regulate the basal levels of the responsive genes CPT-1 and mtHMGS. When more than 6-fold additional PPAR was present, basal CPT-1 and mtHMGS mRNAs were induced by more than 20-fold. Moreover, treatment with ligand stimulated an additional 5-fold induction of mtHMGS but not FACO mRNA or the other peroxisome proliferation-associated genes after PPAR overexpression. Thus, CPT-1 and mtHMGS were regulated over 100-fold without changes in the expression of the peroxisome proliferation-associated genes. Further evidence that refutes the truncated-PPAR hypothesis arises from studies that have demonstrated that human cells transfected with a rat FACO PPRE are responsive to PPAR agonist treatment by inducing the reporter gene construct (22). This regulation was present in either rat or human cell lines and with rat or human PPAR (22, 37). Thus, the human PPAR can regulate the rat PPRE in either mouse or human cells, suggesting that the cellular machinery in both human and rat cells is capable of regulating a promoter containing a functional PPRE.

An attractive hypothesis to explain the species differences in peroxisome proliferation induction suggests that a change in the sequence of the promoter of the acyl-CoA oxidase gene prevents the association of PPAR with the promoter of the peroxisome proliferation-associated genes (12, 13, 37). Our data suggest that additional genes associated with peroxisome proliferation such as HD, THIO, and PMP-70 are likewise unresponsive, even after the overexpression of PPAR. This may be caused by similar sequence defects resulting in the loss of functional PPREs in the respective gene promoters. Alternatively, potential differences in one or more transacting factors (i.e. coactivators or corepressors) could be invoked to explain differences between human and rodent cells that result in relative changes that affect a larger "cassette" of peroxisome proliferation-associated genes.

Our data and those reported previously lead us to hypothesize that the nonresponsive nature of humans and other species (besides rats and mice) to the induction of peroxisome proliferation is based on an evolutionarily controlled deviation intrinsic to cis-acting elements and/or trans-acting factors that are required for the induction of a cassette of genes that regulate fatty acid metabolism mainly involving peroxisomal fatty acid oxidation. Other genes involved in fatty acid and lipid metabolism continue to be controlled by PPAR in the liver of the peroxisome proliferation-resistant species, including humans, and provide a potential pharmacological benefit of PPAR agonist therapy currently used to treat hyperlipidemia. The risk of PPAR agonist-induced peroxisome proliferation and subsequent tumorigenesis seems unlikely given our new understanding of the role of PPAR and its spectrum of responsive genes in non-rodent species. However, further work is required to fully assess the differences in the promoter regions of the genes found to be unresponsive in human liver cells.

	ACKNOWLEDGEMENTS

We gratefully acknowledge the technical assistance of Chhabi Biswas, Gary Dysart, and Kim Bleicher. We also thank John Woods for the anti-PPAR antibody and Wei Han and Conrad Santini for compound 1.

	FOOTNOTES

^* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^§ To whom correspondence may be addressed: Dept. of Safety Assessment, Merck and Co., Inc., Sumneytown Pike, WP45A-201, West Point, PA 19486. Tel.: 215-652-2363; Fax: 215-993-2190; E-mail: jeff_lawrence@merck.com.

To whom correspondence may be addressed: Dept. of Metabolic Disorders, RY80N-C31, Merck and Co., Inc., P.O. Box 2000, Rahway, NJ 07065; Tel.: 732-594-4782; E-mail: gaochao_zhou@merck.com.

Published, JBC Papers in Press, June 19, 2001, DOI 10.1074/jbc.M103306200

	ABBREVIATIONS

The abbreviations used are: PPAR, peroxisome proliferator-activated receptor ; apo CIII, apolipoprotein CIII; PPRE, peroxisome proliferator response element; hPPAR, human PPAR; CHAPS, 3-((3-cholamidopropyl)dimethylammonio)-1-propanesulfonic acid; GST, glutathione S-transferase; LBD, ligand binding domain; CBP, CREB-binding protein; PCR, polymerase chain reaction; RT, reverse transcriptase; FACO, fatty acyl-CoA oxidase; CPT-1, carnitine palmitoyl transferase-1; THIO, peroxisomal 3-oxoacyl-CoA thiolase; HD, peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase; CYP4A, cytochrome P450 4A; PMP-70, peroxisomal membrane protein-70; mtHMGS, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				U. Savas, D. E. W. Machemer, M.-H. Hsu, P. Gaynor, J. M. Lasker, R. H. Tukey, and E. F. Johnson Opposing Roles of Peroxisome Proliferator-activated Receptor {alpha} and Growth Hormone in the Regulation of CYP4A11 Expression in a Transgenic Mouse Model J. Biol. Chem., June 12, 2009; 284(24): 16541 - 16552. [Abstract] [Full Text] [PDF]

				D. M. Selva and G. L. Hammond Peroxisome-Proliferator Receptor {gamma} Represses Hepatic Sex Hormone-Binding Globulin Expression Endocrinology, May 1, 2009; 150(5): 2183 - 2189. [Abstract] [Full Text] [PDF]

				X. Palomer, D. Alvarez-Guardia, R. Rodriguez-Calvo, T. Coll, J. C. Laguna, M. M. Davidson, T. O. Chan, A. M. Feldman, and M. Vazquez-Carrera TNF-{alpha} reduces PGC-1{alpha} expression through NF-{kappa}B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model Cardiovasc Res, March 1, 2009; 81(4): 703 - 712. [Abstract] [Full Text] [PDF]

				A. Koch, B. Konig, J. Spielmann, A. Leitner, G. I. Stangl, and K. Eder Thermally Oxidized Oil Increases the Expression of Insulin-Induced Genes and Inhibits Activation of Sterol Regulatory Element-Binding Protein-2 in Rat Liver J. Nutr., September 1, 2007; 137(9): 2018 - 2023. [Abstract] [Full Text] [PDF]

				S. Luci, B. Giemsa, H. Kluge, and K. Eder Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2007; 293(1): R70 - R77. [Abstract] [Full Text] [PDF]

				Y. Guo, R. A. Jolly, B. W. Halstead, T. K. Baker, J. P. Stutz, M. Huffman, J. N. Calley, A. West, H. Gao, G. H. Searfoss, et al. Underlying Mechanisms of Pharmacology and Toxicity of a Novel PPAR Agonist Revealed Using Rodent and Canine Hepatocytes Toxicol. Sci., April 1, 2007; 96(2): 294 - 309. [Abstract] [Full Text] [PDF]

				S. Subramanian, M. A. DeRosa, C. Bernal-Mizrachi, N. Laffely, W. T. Cade, K. E. Yarasheski, P. E. Cryer, and C. F. Semenkovich PPAR{alpha} activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1365 - E1371. [Abstract] [Full Text] [PDF]

				H. Wintz, L. J. Yoo, A. Loguinov, Y.-Y. Wu, J. A. Steevens, R. D. Holland, R. D. Beger, E. J. Perkins, O. Hughes, and C. D. Vulpe Gene Expression Profiles in Fathead Minnow Exposed to 2,4-DNT: Correlation with Toxicity in Mammals Toxicol. Sci., November 1, 2006; 94(1): 71 - 82. [Abstract] [Full Text] [PDF]

				F. Xu, V. Y. Ng, D. L. Kroetz, and P. R. O. de Montellano CYP4 Isoform Specificity in the {omega}-Hydroxylation of Phytanic Acid, a Potential Route to Elimination of the Causative Agent of Refsum's Disease J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 835 - 839. [Abstract] [Full Text] [PDF]

				Y. Xu, L. Lu, C. Greyson, M. Rizeq, K. Nunley, B. Wyatt, M. R. Bristow, C. S. Long, and G. G. Schwartz The PPAR-{alpha} activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1798 - H1807. [Abstract] [Full Text] [PDF]

				B. Knight, B. B. Yeap, G. C. Yeoh, and J. K. Olynyk Inhibition of adult liver progenitor (oval) cell growth and viability by an agonist of the peroxisome proliferator activated receptor (PPAR) family member {gamma}, but not {alpha} or {delta} Carcinogenesis, October 1, 2005; 26(10): 1782 - 1792. [Abstract] [Full Text] [PDF]

				Y. Cheon, T. Y. Nara, M. R. Band, J. E. Beever, M. A. Wallig, and M. T. Nakamura Induction of overlapping genes by fasting and a peroxisome proliferator in pigs: evidence of functional PPAR{alpha} in nonproliferating species Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1525 - R1535. [Abstract] [Full Text] [PDF]

				J. Zhang, C. Wang, P. L. Terroni, F. R. A. Cagampang, M. Hanson, and C. D. Byrne High-unsaturated-fat, high-protein, and low-carbohydrate diet during pregnancy and lactation modulates hepatic lipid metabolism in female adult offspring Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2005; 288(1): R112 - R118. [Abstract] [Full Text] [PDF]

				M. T. Bility, J. T. Thompson, R. H. McKee, R. M. David, J. H. Butala, J. P. Vanden Heuvel, and J. M. Peters Activation of Mouse and Human Peroxisome Proliferator-Activated Receptors (PPARs) by Phthalate Monoesters Toxicol. Sci., November 1, 2004; 82(1): 170 - 182. [Abstract] [Full Text] [PDF]

				J. Shoda, Y. Inada, A. Tsuji, H. Kusama, T. Ueda, T. Ikegami, H. Suzuki, Y. Sugiyama, D. E. Cohen, and N. Tanaka Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPAR{alpha}-mediated redistribution of ABCB4 J. Lipid Res., October 1, 2004; 45(10): 1813 - 1825. [Abstract] [Full Text] [PDF]

				D. J. Hoivik, C. W. Qualls Jr, R. C. Mirabile, N. F. Cariello, C. L. Kimbrough, H. M. Colton, S. P. Anderson, M. J. Santostefano, R. J. O. Morgan, R. R. Dahl, et al. Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys Carcinogenesis, September 1, 2004; 25(9): 1757 - 1769. [Abstract] [Full Text] [PDF]

				S. Mandard, F. Zandbergen, N. S. Tan, P. Escher, D. Patsouris, W. Koenig, R. Kleemann, A. Bakker, F. Veenman, W. Wahli, et al. The Direct Peroxisome Proliferator-activated Receptor Target Fasting-induced Adipose Factor (FIAF/PGAR/ANGPTL4) Is Present in Blood Plasma as a Truncated Protein That Is Increased by Fenofibrate Treatment J. Biol. Chem., August 13, 2004; 279(33): 34411 - 34420. [Abstract] [Full Text] [PDF]

				H. M. Colton, J. G. Falls, H. Ni, P. Kwanyuen, D. Creech, E. McNeil, W. M. Casey, G. Hamilton, and N. F. Cariello Visualization and Quantitation of Peroxisomes Using Fluorescent Nanocrystals: Treatment of Rats and Monkeys with Fibrates and Detection in the Liver Toxicol. Sci., July 1, 2004; 80(1): 183 - 192. [Abstract] [Full Text] [PDF]

				C. Cheung, T. E. Akiyama, J. M. Ward, C. J. Nicol, L. Feigenbaum, C. Vinson, and F. J. Gonzalez Diminished Hepatocellular Proliferation in Mice Humanized for the Nuclear Receptor Peroxisome Proliferator-Activated Receptor {alpha} Cancer Res., June 1, 2004; 64(11): 3849 - 3854. [Abstract] [Full Text] [PDF]

				M. Ammerschlaeger, J. Beigel, K.-U. Klein, and S. O. Mueller Characterization of the Species-Specificity of Peroxisome Proliferators in Rat and Human Hepatocytes Toxicol. Sci., April 1, 2004; 78(2): 229 - 240. [Abstract] [Full Text] [PDF]

				R. L. Brent Utilization of Animal Studies to Determine the Effects and Human Risks of Environmental Toxicants (Drugs, Chemicals, and Physical Agents) Pediatrics, April 1, 2004; 113(4/S1): 984 - 995. [Abstract] [Full Text] [PDF]

				M. Shimizu, A. Takeshita, T. Tsukamoto, F. J. Gonzalez, and T. Osumi Tissue-Selective, Bidirectional Regulation of PEX11{alpha} and Perilipin Genes through a Common Peroxisome Proliferator Response Element Mol. Cell. Biol., February 1, 2004; 24(3): 1313 - 1323. [Abstract] [Full Text] [PDF]

				J. Zhang, D. I. W. Phillips, C. Wang, and C. D. Byrne Human skeletal muscle PPAR{alpha} expression correlates with fat metabolism gene expression but not BMI or insulin sensitivity Am J Physiol Endocrinol Metab, February 1, 2004; 286(2): E168 - E175. [Abstract] [Full Text] [PDF]

				E. H. Koh, M.-S. Kim, J.-Y. Park, H. S. Kim, J.-Y. Youn, H.-S. Park, J. H. Youn, and K.-U. Lee Peroxisome Proliferator-Activated Receptor (PPAR)-{alpha} Activation Prevents Diabetes in OLETF Rats: Comparison With PPAR-{gamma} Activation Diabetes, September 1, 2003; 52(9): 2331 - 2337. [Abstract] [Full Text] [PDF]

				G. A. Francis, J.-S. Annicotte, and J. Auwerx PPAR-{alpha} effects on the heart and other vascular tissues Am J Physiol Heart Circ Physiol, June 5, 2003; 285(1): H1 - H9. [Abstract] [Full Text] [PDF]

				N. Vu-Dac, P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al. Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor alpha Activators J. Biol. Chem., May 9, 2003; 278(20): 17982 - 17985. [Abstract] [Full Text] [PDF]

				O. Ziouzenkova, S. Perrey, L. Asatryan, J. Hwang, K. L. MacNaul, D. E. Moller, D. J. Rader, A. Sevanian, R. Zechner, G. Hoefler, et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an antiinflammatory role for lipoprotein lipase PNAS, March 4, 2003; 100(5): 2730 - 2735. [Abstract] [Full Text] [PDF]

				J.-M. Ye, M. A. Iglesias, D. G. Watson, B. Ellis, L. Wood, P. B. Jensen, R. V. Sorensen, P. J. Larsen, G. J. Cooney, K. Wassermann, et al. PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E531 - E540. [Abstract] [Full Text] [PDF]

				I. Pineda Torra, T. Claudel, C. Duval, V. Kosykh, J.-C. Fruchart, and B. Staels Bile Acids Induce the Expression of the Human Peroxisome Proliferator-Activated Receptor {alpha} Gene via Activation of the Farnesoid X Receptor Mol. Endocrinol., February 1, 2003; 17(2): 259 - 272. [Abstract] [Full Text] [PDF]

				H. Huang, O. Starodub, A. McIntosh, A. B. Kier, and F. Schroeder Liver Fatty Acid-binding Protein Targets Fatty Acids to the Nucleus. REAL TIME CONFOCAL AND MULTIPHOTON FLUORESCENCE IMAGING IN LIVING CELLS J. Biol. Chem., August 2, 2002; 277(32): 29139 - 29151. [Abstract] [Full Text] [PDF]

				K. Tordjman, K. N. Standley, C. Bernal-Mizrachi, T. C. Leone, T. Coleman, D. P. Kelly, and C. F. Semenkovich PPAR{alpha} suppresses insulin secretion and induces UCP2 in insulinoma cells J. Lipid Res., June 1, 2002; 43(6): 936 - 943. [Abstract] [Full Text] [PDF]

				O. Barbier, I. P. Torra, Y. Duguay, C. Blanquart, J.-C. Fruchart, C. Glineur, and B. Staels Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors in Lipid Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., May 1, 2002; 22(5): 717 - 726. [Abstract] [Full Text] [PDF]

				S. Yu, W.-Q. Cao, P. Kashireddy, K. Meyer, Y. Jia, D. E. Hughes, Y. Tan, J. Feng, A. V. Yeldandi, M. S. Rao, et al. Human Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Supports the Induction of Peroxisome Proliferation in PPARalpha -deficient Mouse Liver J. Biol. Chem., November 2, 2001; 276(45): 42485 - 42491. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 276/34/31521    most recent M103306200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawrence, J. W. Articles by Zhou, G. Search for Related Content PubMed PubMed Citation Articles by Lawrence, J. W. Articles by Zhou, G. Social Bookmarking                      What's this?